Drug Induced Liver Injury - Evaluation

Key Points

• DILI is a diagnosis of exclusion requiring a complete medication, supplement, and toxin timeline.
• Use the R ratio to classify hepatocellular, cholestatic, or mixed injury near presentation.
• Stop the suspected culprit and unnecessary hepatotoxic agents.
• Jaundice plus hepatocellular injury without another explanation raises concern for severe DILI and Hy’s law.
• Encephalopathy plus coagulopathy suggests acute liver failure and requires urgent transplant-center contact.
• Do not rechallenge after severe DILI unless an essential therapeutic need is reviewed by a specialist.
• Herbal and dietary supplements are important causes and must be asked about explicitly.

Algorithm

1. List every drug, supplement, dose change, and intermittent exposure with start and stop dates.
2. Calculate the R ratio from early ALT and alkaline phosphatase values.
3. Exclude viral hepatitis, ischemia, obstruction, autoimmune disease, alcohol-related injury, and other pattern-specific causes.
4. Stop plausible culprit agents.
5. Trend bilirubin, INR, liver enzymes, renal function, and symptoms.
6. Escalate urgently for encephalopathy, rising INR, severe jaundice, or multi-organ dysfunction.
7. Consider biopsy or specialist causality tools when diagnosis remains uncertain.
8. Document and report the reaction and avoid unplanned rechallenge.

Clinical Synopsis & Reasoning

Drug-induced liver injury can be caused by prescription drugs, over-the-counter medications, herbal products, dietary supplements, and recreational exposures. It can mimic nearly every form of acute or chronic liver disease. The diagnosis therefore depends on a meticulous exposure timeline plus exclusion of competing causes. Ask specifically about intermittent antibiotics, acetaminophen-containing combinations, bodybuilding and weight-loss supplements, herbal products, recent dose changes, and medications already stopped before presentation.

Classify the biochemical pattern using the R ratio: ALT divided by its upper limit of normal, divided by alkaline phosphatase divided by its upper limit of normal. An R ratio of at least 5 is hepatocellular, 2 or less is cholestatic, and between 2 and 5 is mixed. The pattern narrows the differential and helps identify known drug phenotypes. It can evolve over time, so use values near onset.

Severe hepatocellular injury with jaundice is concerning for Hy’s law when there is no better cause or substantial cholestasis. Encephalopathy and INR elevation indicate possible acute liver failure and require urgent transplant-center evaluation. Eosinophilia, rash, fever, and facial edema suggest a systemic hypersensitivity syndrome such as DRESS. Autoantibodies and elevated IgG can occur in both autoimmune hepatitis and drug-induced autoimmune-like hepatitis, sometimes requiring biopsy and specialist interpretation.

Treatment Strategy & Disposition

Stop the suspected culprit and other nonessential hepatotoxic exposures. Most idiosyncratic DILI improves with withdrawal and supportive care. There is no universal antidote. Give NAC for acetaminophen toxicity and consider it in adults with early acute liver failure from other causes according to ALF practice. Carnitine, cholestyramine, corticosteroids, or other targeted therapies have roles only in selected drug-specific syndromes and should not be applied broadly.

Trend ALT, AST, alkaline phosphatase, bilirubin, INR, creatinine, and symptoms. Worsening bilirubin or INR despite falling aminotransferases can indicate loss of viable hepatic mass rather than recovery. Admit patients with coagulopathy, encephalopathy, severe jaundice, intractable vomiting, AKI, systemic hypersensitivity, or uncertain ability to follow closely. Refer suspected ALF urgently to a transplant center.

Avoid deliberate rechallenge after severe DILI because recurrence can be faster and more severe. Rechallenge may be considered only when the medication is essential and there is no equivalent alternative, typically under specialist supervision. Report serious suspected DILI through appropriate pharmacovigilance systems and provide the patient a clear written record of the implicated agent and reaction.

Epidemiology / Risk Factors

• Antibiotics, antiepileptics, antituberculous drugs, immunotherapies, and supplements are frequent DILI categories.
• Idiosyncratic DILI is uncommon for any individual medication but important across the population because drug exposure is widespread.
• Herbal and dietary supplement-associated liver injury has become increasingly recognized.
• Older age, underlying liver disease, genetics, and drug-specific factors influence susceptibility variably.

Investigations

R Ratio Categories

Pharmacology

Prognosis / Complications

• Most patients recover after drug withdrawal, but cholestatic injury can resolve slowly over months.
• Hepatocellular injury with jaundice has a higher risk of death or transplantation than mild enzyme elevation alone.
• ALF from DILI may require emergency liver transplantation.
• Chronic DILI can occur, especially after prolonged cholestatic or autoimmune-like injury.

Patient Education / Counseling

• Provide the exact name of the suspected drug or supplement and advise against self-rechallenge.
• Review combination products to prevent accidental re-exposure.
• Avoid alcohol and nonessential supplements while liver tests recover.
• Seek urgent care for confusion, bleeding, worsening jaundice, severe vomiting, or reduced urine output.
• Ensure follow-up laboratory testing until values clearly resolve or stabilize.

Notes

DILI assessment succeeds or fails on exposure history. Medication reconciliation that captures only the current prescription list misses recently completed antibiotics, supplements, and intermittent products that may be the true cause.

AASLD guidance emphasizes that DILI has no single diagnostic biomarker. Pattern, timing, exclusion of alternatives, and dechallenge are integrated to reach the most defensible diagnosis.

Causality assessment should continue after discharge because the clinical course can clarify the diagnosis. A convincing dechallenge, in which liver tests improve after the suspected agent is withdrawn, strengthens the case but is not proof because viral and ischemic injuries can improve on the same timeline. Conversely, cholestatic DILI may remain abnormal for months despite correct withdrawal. Patients with persistent abnormalities should be evaluated for chronic DILI, vanishing bile duct syndrome, autoimmune-like hepatitis, or an alternative chronic liver disease. When several agents are plausible, document the relative likelihood of each rather than permanently labeling every medication as an allergy without evidence.

References

1. AASLD Practice Guidance on Drug, Herbal, and Dietary Supplement-Induced Liver Injury — Link
2. AASLD Liver Fellow Network DILI Guideline Review, 2026 — Link